Are you living with major depressive disorder (MDD)? Are you experiencing persistent sadness, hopelessness, irritability, restlessness, guilt or worthlessness? Indago is
collaborating with Axsome Therapeutics on a research study to assess the safety of solriamfetol in adults with depression (SOL-MDD-301 or PARADIGM).
What is the PARADIGM depression research study?
The PARADIGM study is a clinical research study currently being conducted at select centers in the US. The study is for people aged 18 to 65 who are currently experiencing the symptoms of depression*. The PARADIGM study is to assess the safety of solriamfetol for the treatment of major depressive disorder in adults
*Other criteria also apply.
What are the symptoms of depression?
Adults living with depression may experience some or all of the following symptoms, most of the day, nearly every day, for at least two weeks:1
– Persistent sadness
– Feelings of hopelessness
– Feelings of irritability or restlessness
– Feelings of guilt or worthlessness
– Loss of interest or pleasure in hobbies and activities
– Decreased energy or fatigue
– Difficulty concentrating, remembering, or making decisions
– Difficulty sleeping or oversleeping
– Changes in appetite or unplanned weight changes
Not everyone who is depressed experiences the symptoms listed above and this is not an exhaustive list
Who Can Participate?
People who are aged 18 to 65 in the U.S. who are currently experiencing symptoms of depression may be eligible. Other criteria also apply.
Why Participate?
If you’re living with depression, the PARADIGM study may be right for you. If you are eligible to participate:
- You may receive the investigational medication.
- You may receive study-related care and study evaluations at no cost.
- You may also receive compensation for your time and travel.
- You may have the opportunity to help advance potential new treatments for people with depression*.
*Solriamfetol is an investigational oral medication being studied for major depressive disorder.
Call us for more information: 786-772-0510
1. Institute of Health Metrics and Evaluation. Global Health Data Exchange (GHDx). http://ghdx.healthdata.org/gbd-results-tool?params=gbd-api-2019-permalink/d780dffbe8a381b25e1416884959e88b (Accessed 1 May 2021).
